8-K: enGene Reports Q3 2025 Results, LEGEND Trial Progress

enGene Holdings Inc. announced its third-quarter 2025 financial results, highlighted by target enrollment in its pivotal LEGEND trial and RMAT designation for detalimogene.

Summary

• Achieved target enrollment milestone of 100 patients for the LEGEND trial's pivotal cohort in high-risk BCG-unresponsive NMIBC with carcinoma in situ.
• Detalimogene was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA.
• Cash and marketable securities totaled $224.9 million as of July 31, 2025, expected to provide a runway into 2027.
• Net loss attributable to common shareholders for the third quarter ended July 31, 2025, was $28.9 million, or $0.57 per share.
• Total operating expenses for the quarter were $29.9 million, an increase from $16.8 million in the prior year's quarter.

Sentiment

Score: 7

Explanation: The company achieved significant clinical and regulatory milestones with target enrollment in its pivotal LEGEND trial and RMAT designation for detalimogene, which are strong indicators of future potential. However, this progress comes with increased operating expenses and a higher net loss, which is typical for a clinical-stage biotech advancing its lead program. The cash runway into 2027 provides stability.

Positives

• Achieved target enrollment milestone of 100 patients in the pivotal Cohort 1 of the LEGEND trial for high-risk, BCG-unresponsive NMIBC carcinoma in-situ (CIS) with or without concomitant papillary disease.
• Detalimogene voraplasmid received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for high-risk, BCG-unresponsive NMIBC with CIS, which provides regulatory advantages including early and frequent FDA engagement, potential for rolling submission, and priority review.
• Existing cash, cash equivalents, and marketable securities of $224.9 million as of July 31, 2025, are expected to fund operating expenses, debt obligations, and capital expenditures into 2027.
• Key board and management appointments were made to support the strategic transition towards the planned commercialization of detalimogene.

Negatives

• Total operating expenses increased to $29.9 million for the three months ended July 31, 2025, compared to $16.8 million for the same period in 2024, primarily due to increasing manufacturing and clinical costs related to the LEGEND study and personnel-related costs.
• Net loss attributable to common shareholders increased to $28.9 million, or $0.57 per share, for the three months ended July 31, 2025, compared to $14.1 million, or $0.32 per share, for the same period in 2024.

Risks

• Ability to recruit and retain qualified scientific and management personnel.
• Ability to establish clinical trial sites and enroll patients in clinical trials.
• Ability to execute on clinical development plans and secure regulatory approval on anticipated timelines.
• Other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission (SEC) on EDGAR, including those described in the Risk Factors section of the Annual Report on Form 10-K for the fiscal year ended October 31, 2024.

Future Outlook

The company anticipates providing an updated preliminary data from the LEGEND trial's pivotal cohort in Q4 2025, along with trial in progress updates from additional cohorts. A Biologic License Application (BLA) filing for the LEGEND pivotal cohort is planned for the second half of 2026. Existing cash and marketable securities are projected to fund operations into 2027.

Management Comments

• "Reaching target enrollment in LEGEND's pivotal Cohort 1 and securing RMAT designation are important milestones that mark our continued momentum." Ron Cooper, Chief Executive Officer.
• "We look forward to providing a data update from the LEGEND pivotal cohort later this year." Ron Cooper, Chief Executive Officer.
• "These advances bring us closer to our planned BLA filing in 2026 with the ultimate goal of delivering detalimogene to patients as a therapy designed for efficacy, safety, and ease-of-use." Ron Cooper, Chief Executive Officer.

Industry Context

The RMAT designation for detalimogene highlights its potential to address a significant unmet medical need in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), a disease with high recurrence rates and substantial economic burden. This positions enGene favorably in the competitive landscape of gene therapies for oncology, particularly given the advantages of its non-viral DDX platform over traditional viral-based gene therapies in terms of handling, storage, manufacturing, and administration.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value due to significant clinical and regulatory progress (LEGEND enrollment, RMAT designation) and a clear path towards BLA filing, but also increased financial losses.
• Patients (NMIBC): Detalimogene's progress offers hope for a new, potentially more effective and easier-to-use treatment option for high-risk, BCG-unresponsive NMIBC, addressing a high unmet medical need.
• Employees: Promotions and new board appointments indicate growth and strategic focus, potentially positive for employee morale and career development.

Next Steps

• Provide updated preliminary data from LEGEND trial's pivotal cohort in Q4 2025.
• Provide trial in progress updates from LEGEND's additional cohorts (HR-NMIBC patients with CIS who are naive to treatment with BCG (Cohort 2a); HR-NMIBC patients with CIS who have been exposed to BCG but have not received adequate BCG treatment (Cohort 2b); and BCG-unresponsive HR-NMIBC patients with papillary-only disease (Cohort 3)) in Q4 2025.
• Plan Biologic License Application (BLA) filing for LEGEND's pivotal cohort in 2H 2026.

Key Dates

Recommendation

While the achievement of target enrollment in the pivotal LEGEND trial and the RMAT designation for detalimogene are significant positive catalysts, indicating strong clinical progress and an expedited regulatory pathway, the company is still in a clinical stage with increasing operating expenses and net losses. The cash runway into 2027 provides stability, but investors should await the Q4 2025 data update from the LEGEND pivotal cohort for further de-risking before considering a stronger position. The current stage warrants a 'hold' to observe upcoming clinical data and further progress towards BLA filing.

Keywords

enGene Holdings, ENGN, Biotechnology, Gene Therapy, NMIBC, Bladder Cancer, Detalimogene, LEGEND trial, RMAT designation, Clinical-stage, Financial Results, Q3 2025, FDA, Oncology